Nano-based delivery of RNAi in cancer therapy
Abstract Background RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-07-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12943-017-0683-y |
| _version_ | 1818031234083717120 |
|---|---|
| author | Yong Xin Min Huang Wen Wen Guo Qian Huang Long zhen Zhang Guan Jiang |
| author_facet | Yong Xin Min Huang Wen Wen Guo Qian Huang Long zhen Zhang Guan Jiang |
| author_sort | Yong Xin |
| collection | DOAJ |
| description | Abstract Background RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are capable of mediating effective RNAi with targeting potential, are attracting extensive interest. Objective This review presents an overview of the mechanisms of RNAi molecules in gene therapy and the different nanoparticles used to deliver RNAi molecules; briefly describes the current uses of RNAi in cancer therapy along with the nano-based delivery of RNA molecules in previous studies; and highlights some other carriers that have been applied in clinical settings. Finally, we discuss the nano-based delivery of RNAi therapeutics in preclinical development, including the current status and limitations of anti-cancer treatment. Conclusion With the growing number of RNAi therapeutics entering the clinical phase, various nanocarriers are expected to play important roles in the delivery of RNAi molecules for cancer therapeutics. |
| first_indexed | 2024-12-10T05:48:14Z |
| format | Article |
| id | doaj.art-f13d1acbb9d3474ba808887d0cd64eaf |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-10T05:48:14Z |
| publishDate | 2017-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-f13d1acbb9d3474ba808887d0cd64eaf2022-12-22T02:00:06ZengBMCMolecular Cancer1476-45982017-07-011611910.1186/s12943-017-0683-yNano-based delivery of RNAi in cancer therapyYong Xin0Min Huang1Wen Wen Guo2Qian Huang3Long zhen Zhang4Guan Jiang5Hospital of Xuzhou Medical UniversityHospital of Xuzhou Medical UniversityHospital of Xuzhou Medical UniversityHospital of Xuzhou Medical UniversityHospital of Xuzhou Medical UniversityDepartment of Dermatology, Affiliated Hospital of Xuzhou Medical UniversityAbstract Background RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are capable of mediating effective RNAi with targeting potential, are attracting extensive interest. Objective This review presents an overview of the mechanisms of RNAi molecules in gene therapy and the different nanoparticles used to deliver RNAi molecules; briefly describes the current uses of RNAi in cancer therapy along with the nano-based delivery of RNA molecules in previous studies; and highlights some other carriers that have been applied in clinical settings. Finally, we discuss the nano-based delivery of RNAi therapeutics in preclinical development, including the current status and limitations of anti-cancer treatment. Conclusion With the growing number of RNAi therapeutics entering the clinical phase, various nanocarriers are expected to play important roles in the delivery of RNAi molecules for cancer therapeutics.http://link.springer.com/article/10.1186/s12943-017-0683-yNanocarriersRNAisiRNAmiRNACancer therapyGene therapy |
| spellingShingle | Yong Xin Min Huang Wen Wen Guo Qian Huang Long zhen Zhang Guan Jiang Nano-based delivery of RNAi in cancer therapy Molecular Cancer Nanocarriers RNAi siRNA miRNA Cancer therapy Gene therapy |
| title | Nano-based delivery of RNAi in cancer therapy |
| title_full | Nano-based delivery of RNAi in cancer therapy |
| title_fullStr | Nano-based delivery of RNAi in cancer therapy |
| title_full_unstemmed | Nano-based delivery of RNAi in cancer therapy |
| title_short | Nano-based delivery of RNAi in cancer therapy |
| title_sort | nano based delivery of rnai in cancer therapy |
| topic | Nanocarriers RNAi siRNA miRNA Cancer therapy Gene therapy |
| url | http://link.springer.com/article/10.1186/s12943-017-0683-y |
| work_keys_str_mv | AT yongxin nanobaseddeliveryofrnaiincancertherapy AT minhuang nanobaseddeliveryofrnaiincancertherapy AT wenwenguo nanobaseddeliveryofrnaiincancertherapy AT qianhuang nanobaseddeliveryofrnaiincancertherapy AT longzhenzhang nanobaseddeliveryofrnaiincancertherapy AT guanjiang nanobaseddeliveryofrnaiincancertherapy |